Invesco Mutual Fund has launched the Invesco India Pharma and Healthcare Fund, an open-ended equity scheme investing in pharma, healthcare and allied sectors. The New Fund Offer (NFO) opened for subscription on August 18, 2026, and will close on September 1, 2026. According to reports from The Hindu BusinessLine, the fund will be managed by Aditya Khemani, Head of Equity & Fund Manager at Invesco Mutual Fund, and will be benchmarked against the BSE Healthcare TRI. The scheme requires a minimum lump-sum investment of ₹1,000 and minimum SIP investment of ₹100.
The fund will invest across pharmaceutical companies, hospitals, diagnostics, contract development and manufacturing organisations (CDMOs), contract research organisations (CROs), medical devices, healthcare services, insurance and other allied healthcare segments. As reported by The Hindu BusinessLine, the fund seeks to capitalise on India's evolving healthcare ecosystem, which is being shaped by favourable demographics, expanding healthcare access and rising insurance penetration. The fund house confirmed that the scheme has a very high risk classification and is intended for investors seeking long-term capital appreciation through predominantly equity and equity-related investments in pharma, healthcare and allied companies. The investment approach will focus on identifying quality businesses with sustainable competitive advantages and strong growth visibility across the healthcare ecosystem.
Speaking at the launch, Aditya Khemani, Head of Equity & Fund Manager, Invesco Mutual Fund, highlighted the structural transformation in India's healthcare sector. According to The Hindu BusinessLine, Khemani stated that India's healthcare sector is undergoing structural transformation with rising healthcare consumption driven by favourable demographics and increasing affordability. The country is strengthening its position as a global pharmaceutical and healthcare innovation hub, with India today occupying a unique position in the global healthcare ecosystem, supported by its scale, talent pool, manufacturing capabilities and growing innovation footprint. The investment approach will focus on identifying quality businesses with sustainable competitive advantages and strong growth visibility across the healthcare ecosystem.
The fund has a 0.50% exit load if redeemed/switched out within 3 months, with nil exit load after 3 months. As reported by The Hindu BusinessLine, the scheme is supported by factors including rising healthcare expenditure, ageing demographics, increasing lifestyle diseases, wider health insurance coverage, infrastructure development and India's growing role in global pharmaceutical outsourcing. The fund is not restricted to traditional pharmaceutical companies and allows investment across different parts of the healthcare value chain.
According to reports from The Hindu BusinessLine, Invesco Asset Management (India) had ₹1,57,943 crore of average assets under management for the quarter ended March 2026, across mutual funds, PMS and offshore advisory. The fund is positioned as a sector-focused equity fund rather than a diversified equity scheme, and as a new fund, it has no historical performance track record. The eventual performance will need to be assessed against its BSE Healthcare TRI benchmark and the broader performance of the healthcare sector.
